Epitalon (Epithalon)
Epithalon, Epithalone, AEDG peptide, Ala-Glu-Asp-Gly, synthetic analog of Epithalamin (pineal extract)
The Ground Truth Score
four plain questions, never one numberBig longevity story, borrowed evidence
Bottom line
A pineal tetrapeptide with genuinely interesting in-vitro telomere data and decades of animal work, but almost no controlled human evidence for the synthetic molecule itself, and the famous human mortality numbers came from a different compound (the pineal extract epithalamin), not Epitalon.
Does the science back it?
Do real people feel it?
Is it safe?
Could it be placebo?
Can you legally get it?
Advisory: yesRecommended, not legal yetAn FDA advisory committee recommended this for the 503A Bulks List in July 2026. Read that precisely: it is a recommendation, not a rule. Nothing changed about what is legal, FDA still has to run notice-and-comment rulemaking, and it can decline. Today this is still bought the same gray-market way it was in June.
Recommended for the 503A Bulks List by the FDA's Pharmacy Compounding Advisory Committee, 7-5, one abstention, at the July 23-24 2026 meeting. FDA's own briefing documents recommended against adding it. The vote is advisory and binds nothing.
Legal status as of 2026-07-24. This is a separate axis from the grades above, and it does not move them. A vote about who may legally prepare a compound is not evidence that the compound works.
"Do real people feel it?" is anecdote, not proof, weighted up because the science is thin, never because it beats a trial. And "could it be placebo?" is not an insult: if you feel better, that's real to you. The point is only to know whether you're paying peptide prices for an expectation.
Why is the evidence this thin? It's mostly economics →
Dose at a glance
full dosing ↓Most commonly reported protocol is 5-10 mg per day subcutaneously for 10-20 consecutive days, run as a short course once or twice per year rather than continuously; a frequent variant is 10 mg/day for 10 days.
Reported, not prescribed. Verify your vial and your math.
First documented human use
No modern randomized, placebo-controlled human trial of synthetic Epitalon (AEDG) has been completed or registered on ClinicalTrials.gov. The earliest documented human use traces to Vladimir Khavinson's group at the St. Petersburg Institute of Bioregulation and Gerontology in the late 1990s-2000s (e.g., a parabulbar-injection retinitis pigmentosa series and a sublingual circadian-rhythm study), all non-blinded, non-randomized, and from a single research group. The widely-cited "elderly mortality reduction" cohorts (~266 subjects; Korkushko 12-year follow-up) used EPITHALAMIN, the bovine pineal extract, not the synthetic Epitalon peptide most people inject today.
The pitch
What people claim it does
Stated plainly and neutrally, exactly as you'll hear it. We grade each one below.
- A synthetic tetrapeptide (Ala-Glu-Asp-Gly) modeled on a pineal-gland extract, marketed for healthy aging and longevity.
- In cultured human cells it has been reported to activate telomerase and elongate telomeres, letting fibroblasts divide past the usual Hayflick limit.
- Most commonly taken in short annual or semi-annual cycles rather than continuously, aiming to 'reset' regulatory pathways.
- Users most often run it for sleep quality and a general anti-aging hope rather than any single measurable endpoint.
- Frequently bundled with other peptides in longevity stacks, which makes individual attribution difficult.
The data behind each bullet
What actually backs it
In vitro, Epitalon activates telomerase in human somatic cells and elongates telomeres, allowing cultured fibroblasts to divide beyond the typical Hayflick limit (e.g., past passage 44 vs ~34 in controls).
Reproducible in cell-culture and a 2025 multi-cell-line replication, but this is in-vitro/mechanistic evidence, not a clinical outcome. Telomere elongation in a dish does not establish lifespan or healthspan benefit in people.
PubMed: Epitalon telomerase telomere human cells ↗Decades of rodent and Drosophila studies report extended mean/maximum lifespan, reduced spontaneous tumor incidence, and fewer chromosomal aberrations.
Consistent but animal-only, and overwhelmingly produced by one research group (Khavinson/Anisimov). Strong animal data does not raise the human evidence grade.
PubMed: Epitalon lifespan tumor mice Anisimov ↗Human use of the SYNTHETIC peptide is limited to small, uncontrolled studies: a retinitis pigmentosa injection series (~162 patients, no blinding/randomization reported) and a sublingual circadian/melatonin study (~75 women, placebo-referenced).
These are human pilot/observational data at best, small, single-group, and lacking modern controls. They are the highest-quality direct human evidence for the molecule and still fall short of a proper RCT.
PubMed: Epitalon human melatonin circadian / retinitis ↗The famous 'reduced all-cause mortality in elderly' results came from EPITHALAMIN (bovine pineal extract), not synthetic Epitalon.
This is the single biggest honesty issue: the ~266-subject cohort and the 12-year Korkushko cardiovascular-mortality follow-up tested the extract preparation, then the benefit gets quietly transferred to the injectable tetrapeptide in marketing. Different compound, non-randomized, single group.
PubMed: epithalamin mortality elderly Korkushko ↗A 2023 case report showed a ~7.9-year drop in 'biological age' and a small telomere increase after Epitalon cycles.
n=1, no control, no blinding, and the patient simultaneously received therapeutic plasma exchange, umbilical-cord stem cells/exosomes, and daily Semax, the authors themselves admit causal attribution to Epitalon is unknown. Essentially uninterpretable for this peptide.
Restorative Medicine case report (biological age) ↗No FDA approval for any indication, and no trial registered on ClinicalTrials.gov.
Verified absence, there is no U.S. regulatory authorization and no registered controlled trial of Epitalon. (The related extract epithalamin has some Russia-only clinical use.)
ClinicalTrials.gov search: epitalon / epithalon ↗Prove it
Can you tell if it's working?
The honest test: if it's working, is there any objective way to see it — a blood marker, a scan, a wearable? For a lot of peptides the answer is no, and that's worth knowing before you spend on labs or gear.
The only non-blood readout worth keeping is a urinary melatonin-metabolite (aMT6s) check, and even that is a mechanism proxy, not proof the peptide works; wearable sleep tracking was cut because for epitalon it measures expectation and staging noise, not efficacy.
Bloodwork
Nothing on a routine panel confirms this one. Anyone who says otherwise is guessing.
Epitalon (Ala-Glu-Asp-Gly) is a pineal tetrapeptide bioregulator; its claimed actions are hTERT/telomerase upregulation with telomere elongation and restoration of nocturnal melatonin rhythm. None of those map onto a routine LabCorp/Quest analyte, and it has no known dose-dependent effect on any standard CBC, CMP, lipid, or hormone panel value that would predictably rise or fall as it works.
Read this before you spend on labs
You cannot prove epitalon is working with routine bloodwork. Its two mechanistic readouts are both off the standard menu: telomerase activity and telomere length are research assays (qPCR/flow-FISH, demonstrated mainly in cultured human cells, not orderable at LabCorp/Quest as validated efficacy tests), and leukocyte telomere length carries large inter-person variance and drifts over years, so no individual can attribute a change to a 10-20 day peptide cycle. The one semi-objective human signal, a shift in nocturnal melatonin rhythm, is not a routine panel and rests on weak, single-lab (Russian) evidence for the related preparation epithalamin rather than the tetrapeptide itself. The benefits users actually chase, sleep depth, vitality, and slowed aging, are subjective or unmeasurable on any standard panel. Do not order labs to confirm this one; there is no honest blood proxy.
- Khavinson 2003 - Epithalon peptide induces telomerase activity and telomere elongation in human somatic cells (in vitro fetal fibroblasts, Bull Exp Biol Med) ↗
- Korkushko 2004 - Effect of epithalamin on circadian melatonin rhythm in elderly people (related pineal preparation, not epitalon; Bull Exp Biol Med) ↗
Other ways to track it
Urinary 6-sulfatoxymelatonin (aMT6s) — overnight or first-morning collection, orderable through specialty labs as a non-invasive index of endogenous melatonin output
If the peptide's one semi-objective claimed action holds, you would see overnight aMT6s rise versus your own pre-cycle baseline, indicating higher nocturnal melatonin output. This is strictly a MECHANISM marker: it can show melatonin moved, but it cannot prove the marketed longevity, telomere, or sleep-quality benefit, and the human evidence that epitalon raises melatonin at all is weak, single-lab, and unblinded. A rise is consistent with the mechanism, not confirmation the compound 'works.'
6-sulfatoxymelatonin is the standard, validated non-blood proxy for endogenous melatonin production, which is the specific pathway epitalon is claimed to restore; it directly tests the single mechanism the literature describes, without relying on subjective report.
Bottom line
Beyond blood, there is no validated way to prove epitalon works. Only one honest proxy survives: urinary aMT6s, which objectively indexes the claimed mechanism (nocturnal melatonin output) but is not an efficacy endpoint and rests on weak, single-lab, unblinded human data, so even a clear rise cannot confirm the marketed longevity/telomere benefit. Interpret any positive signal as mechanism-consistent at best, only against a solid personal baseline using multiple collections. Wearable sleep tracking was removed: for this compound it has no controlled human trials, the reported effect is subjective and strongly placebo-prone, consumer sleep staging is unreliable, and it captures expectation and noise rather than the compound's action.
Logging baseline vs retest is the whole game. The Truth Tracker is our free log for bloodwork, DEXA, genetics, and wearable data — bring your own numbers.
How to track it →Mechanism
How it's assumed to work
Assumed · theoretical pathway
Assumed mechanism: Epitalon is proposed to act as a peptide bioregulator that enters cells and influences gene expression, with the headline effect being upregulation of telomerase (hTERT) leading to telomere elongation. Secondary assumed actions include stimulating pineal melatonin synthesis / normalizing circadian rhythm, antioxidant effects, and modulation of immune (IL-2, thymocyte) signaling. Reviewers stress the precise mechanism remains unverified after ~25 years; none of this is established drug pharmacology.
Dosing & handling
What users and clinicians report
Most commonly reported protocol is 5-10 mg per day subcutaneously for 10-20 consecutive days, run as a short course once or twice per year rather than continuously; a frequent variant is 10 mg/day for 10 days. Some users split into smaller daily injections. Sublingual/intranasal forms exist but with even less data. These are REPORTED community/clinic practices, not prescribing guidance, there is no validated human dose.
Doses are derived from tradition and vendor guidance, not from dose-finding human trials, so the 'right' dose is genuinely unknown and the cyclical schedule is a rationalization rather than an evidence-based regimen. Lyophilized peptide must be reconstituted with bacteriostatic water, kept refrigerated after mixing, and protected from heat/light/agitation; mass dosing also depends on accurate vial-size and concentration math, which is a common source of large dosing errors with gray-market peptides.
Timing & food
Commonly dosed in the evening / before bed, on the theory that aligning with the natural nocturnal melatonin rhythm supports the claimed pineal/circadian effects and sleep benefit. Food timing is not considered important for a subcutaneous injection (no GI absorption step), so fasted-vs-fed is largely irrelevant; the evening preference is about circadian rationale, not bioavailability.
Half-life
Not formally characterized in humans. As a small linear tetrapeptide it is expected to be rapidly degraded by peptidases (a short circulating half-life on the order of minutes is plausible), which is part of the rationale for daily dosing during a cycle, but published reference charts list its half-life as 'not well characterized / limited data,' so any specific number is an estimate, not a measured value.
Reconstitution sensitivity
Supplied as a lyophilized powder; reconstitute with bacteriostatic (not sterile-only) water for multi-day use. Sensitive to heat, light, and agitation, swirl rather than shake. Store the vial refrigerated; keep reconstituted solution cold and use within a few weeks. Powder is more stable than solution. Identity and purity of gray-market product are not guaranteed, which is a meaningful real-world handling risk.
Real-world signal
What people actually report
Anecdote, not proof, weighted because the science is thin. Here's the record, graded on volume, consistency, and how credible the sources are.
Volume
Moderate chatter in longevity and peptide communities. Epitalon is a well-known 'name brand' in anti-aging circles, but the volume of substantive, detailed first-hand reports is thinner than for popular recovery or GLP-1 peptides, and a large share of visible content is vendor or affiliate material rather than disinterested user experience.
Consistency
Inconsistent and mostly soft. The most repeated subjective report is better/deeper sleep during a cycle; beyond that, 'feel younger / more energy' is vague and variable. The core selling point, actually living longer or measurably reversing aging, is something individual users cannot perceive, so there is no consistent real-world outcome to point to, only proxy lab numbers that are easy to misattribute.
Source credibility
Low-to-moderate. Sentiment is heavily shaped by vendors and longevity influencers with an incentive to sell, and the strongest-sounding 'human evidence' people cite usually turns out to be the epithalamin extract studies or the confounded n=1 case report. Discounting affiliate sources leaves a modest, mostly-subjective anecdote base. Treat as hypothesis-generating only.
- The most common anecdote is improved sleep depth and more vivid dreams during a 10-20 day cycle, often the first thing users mention (anecdote, not proof).
- Many report a vague 'feel younger / more recovered / more energy' sense that is hard to pin to anything measurable.
- A subset of users say they noticed nothing at all and view the longevity claims as unfalsifiable or placebo, especially given the cost and injection burden.
- Practitioner and biohacker communities tend to treat it as a 'maybe it helps, low felt downside' annual ritual rather than something with a clear, reproducible effect, and frequently can't separate it from the rest of their stack.
Placebo risk, High
Placebo risk is High because the effects users can actually feel, sleep, mood, a sense of vitality, are entirely subjective and expectation-sensitive, and the program (injections, annual 'reset' cycles, longevity framing) strongly primes a positive narrative. The one semi-objective readout, melatonin/circadian change, has only weak controlled support, and 'biological age'/telomere numbers are noisy and confounded. Without blinding, most of the perceived benefit could be expectation.
Risk panel
What could go wrong
Adverse events
Across the small human studies reported, no serious adverse events were documented, the retinitis pigmentosa series explicitly noted no side effects. Community reports cluster on minor, short-lived issues: injection-site redness, brief lethargy in the first few doses, mild headache/dizziness, and occasional first-week sleep changes. None of this comes from rigorous safety monitoring.
Theoretical concerns
The central theoretical concern is mechanistic: anything that upregulates telomerase could, in principle, support survival/proliferation of pre-malignant or malignant cells. Proponents counter with the animal anti-tumor data, but that data is single-group and species-limited, and the cancer-risk question in humans is simply unresolved. There is no genotoxicity or carcinogenicity dataset in humans to lean on either way.
Contraindications
No formal contraindication list exists because it has never gone through proper drug development. Reasonable caution would steer anyone with an active or recent malignancy, or significant cancer risk, away until the telomerase-and-cancer question is answered. Pregnancy, breastfeeding, and pediatric use are uncharacterized and should be treated as off-limits. As an injectable gray-market peptide, sourcing/sterility and reconstitution hygiene are practical risks independent of the molecule itself.
Honest unknowns
Long-term human safety is effectively unknown, there is no multi-year, controlled follow-up on the synthetic peptide. Pharmacokinetics (half-life, distribution, metabolism) are not formally characterized in humans. There are no data on drug interactions, no defined therapeutic window, and no independent verification of purity/identity in gray-market product. The gap between 'no reported harm in tiny studies' and 'demonstrated safe' is very wide here.
Confound watch
Attribution is genuinely hard with this compound. Users almost always run it inside longevity stacks (other peptides like Semax/Selank, GH secretagogues, NAD+ precursors, metformin/rapamycin, melatonin) and concurrently optimize sleep, training, and diet. The headline case report layered Epitalon on top of plasma exchange and stem cells. Any 'biological age' or telomere readout is also lab- and method-dependent and noisy, so improvements are easily mis-credited to Epitalon.
History
Discovery → first use → status
Update: an FDA advisory panel voted in favor of this one on July 23-24, 2026
The FDA's Pharmacy Compounding Advisory Committee voted 7-5, with one abstention to recommend adding this to the 503A Bulks List, meaning compounding pharmacies could legally prepare it. Now read the fine print, because it matters more than the headline. The vote is advisory and changes nothing today: FDA still has to go through formal rulemaking, which can take a year, and it has overruled its own panels before. FDA's own scientists recommended AGAINST adding it, citing thin human evidence and unassessed immunogenicity risk, and the committee voted the other way. That committee is also not neutral: most of its recent appointees work at or run clinics that sell peptide treatments. And none of this is a finding that the compound works. A compounding-eligibility vote is not drug approval, and it is not evidence. Our grade here is unchanged, because the evidence did not change.
Vote recorded July 23-24, 2026; verified against FDA's meeting materials and contemporaneous reporting. Nothing here is final — check the current rule before acting.
FDA — PCAC meeting, July 23-24 2026 ↗- 1970sKhavinson and colleagues isolate 'epithalamin,' a peptide extract from bovine pineal gland, at the St. Petersburg (Leningrad) gerontology institute.
- 1980s-1990sSynthetic tetrapeptide Ala-Glu-Asp-Gly (Epitalon/Epithalon) developed as a defined-sequence analog of the extract's active fraction.
- 2003Bulletin of Experimental Biology and Medicine reports Epitalon induces telomerase activity in human somatic cells in culture.
- 2004Follow-up reports describe Epitalon-treated human fibroblasts dividing beyond the Hayflick limit; rodent lifespan/anti-tumor papers accumulate.
- 2000sSmall uncontrolled human use of the synthetic peptide (retinitis pigmentosa series; sublingual circadian/melatonin study), all from the same group.
- 2017AEDG reported as detectable in vivo; mechanistic gene-expression / epigenetic work continues.
- 2025Independent-style cell-line study re-examines telomere lengthening (telomerase vs ALT pathways), reaffirming the in-vitro signal while underscoring the human-data gap.
Verification
The COA standard, applied
Cross-checked against: an independent Cognitive Vitality (Alzheimer's Drug Discovery Foundation) assessment, two 2024-2025 peer-reviewed PMC review articles, the original Khavinson-group telomerase/lifespan literature, the n=1 restorative-medicine case report, Wikipedia (flagged for over-reliance on primary sources), and a ClinicalTrials.gov / FDA absence check. The epithalamin-vs-Epitalon attribution issue and the lack of registered RCTs were confirmed across multiple independent sources.
The full verification standard →Sources
Where this comes from
- PMC review: Overview of Epitalon, a bioactive pineal tetrapeptide (2024) ↗· Peer-reviewed overview; notes mechanism still unverified, only two small human studies, and that toxicity/safety studies are still needed.
- Cognitive Vitality (Alzheimer's Drug Discovery Foundation): Epithalamin & Epithalon assessment ↗· Independent assessment; flags single-group dominance, lack of blinding/randomization/replication, and limited long-term safety data.
- PubMed search: Epitalon telomerase / telomere in human cells ↗· Primary in-vitro telomerase/telomere literature (Khavinson group + 2025 replication).
- PubMed search: epithalamin mortality in elderly (Korkushko cohorts) ↗· Source of the famous mortality-reduction numbers, note these used the pineal EXTRACT, not synthetic Epitalon.
- Restorative Medicine: n=1 biological-age case report (2023) ↗· Single confounded case (plasma exchange + stem cells + Semax co-administered); authors admit causation is unknown.
- ClinicalTrials.gov search: epitalon / epithalon ↗· Verifies no registered controlled trial; no FDA approval for any indication.
The four lenses reflect the evidence and the real-world record as of the last review and will change as data arrives. Real-world signal and reported feedback are anecdote, not proof. Nothing here is medical advice or a prescription.